Molly Henderson Biography and Net Worth

CFO of UroGen Pharma

Molly is a seasoned financial executive with extensive pharmaceutical industry experience.

Molly previously served as Chief Financial Officer at Advaxis (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products. Prior to Advaxis, Molly was Chief Financial Officer at Iovance Biotherapeutics, Inc., (Nasdaq: IOVA, formerly Lion Biotechnologies, Inc.) an immuno-oncology company. In both these roles, she was responsible for all financial, investor relations, Securities and Exchange Commission reporting, legal, governance, human resources and IT-related functions. Molly has raised over $250 million in capital in support of advancing companies’ missions.

Earlier in her career Molly was Corporate Controller at Ultralife Corporation and has been an expert advisor to entrepreneurs in Switzerland. She holds a Master of Business Administration and bachelor’s degree in Accounting from the University at Buffalo and is on the Board of Directors and Chair of the Audit Committee of Calliditas (Nasdaq: CALT).

Molly started her career at PricewaterhouseCoopers.

What is Molly Henderson's net worth?: The estimated net worth of Molly Henderson is at least $1.05 million as of January 21st, 2025. Ms. Henderson owns 93,546 shares of UroGen Pharma stock worth more than $1,047,715 as of March 29th. This net worth approximation does not reflect any other assets that Ms. Henderson may own. Learn More about Molly Henderson's net worth.
How do I contact Molly Henderson?: The corporate mailing address for Ms. Henderson and other UroGen Pharma executives is 400 Alexander Park, Princeton NJ, 08540. UroGen Pharma can also be reached via phone at (646) 768-9780 and via email at kate.bechtold@urogen.com. Learn More on Molly Henderson's contact information.
Has Molly Henderson been buying or selling shares of UroGen Pharma?: Molly Henderson has not been actively trading shares of UroGen Pharma over the course of the past ninety days. Most recently, Molly Henderson sold 331 shares of the business's stock in a transaction on Monday, January 31st. The shares were sold at an average price of $7.58, for a transaction totalling $2,508.98. Learn More on Molly Henderson's trading history.
Who are UroGen Pharma's active insiders?: UroGen Pharma's insider roster includes Elizabeth Barrett (CEO), Molly Henderson (CFO), Mark Schoenberg (Insider), and Jason Smith (General Counsel). Learn More on UroGen Pharma's active insiders.
Are insiders buying or selling shares of UroGen Pharma?: In the last twelve months, insiders at the sold shares 5 times. They sold a total of 19,463 shares worth more than $231,431.84. The most recent insider tranaction occured on January, 31st when insider Mark Schoenberg sold 4,551 shares worth more than $50,698.14. Insiders at UroGen Pharma own 5.1% of the company. Learn More about insider trades at UroGen Pharma.
Information on this page was last updated on 1/31/2025.

Molly Henderson Insider Trading History at UroGen Pharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/31/2022	Sell	331	$7.58	$2,508.98
11/30/2021	Sell	2,587	$12.03	$31,121.61
5/17/2021	Buy	2,500	$15.85	$39,625.00	2,500

Molly Henderson Buying and Selling Activity at UroGen Pharma

UroGen Pharma Company Overview

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

Today's Range

Now: $11.20

$11.05

$11.55

50 Day Range

MA: $10.66

$9.27

$12.13

2 Week Range

Now: $11.20

$9.03

$20.70

Volume

177,900 shs

Average Volume

500,644 shs

Market Capitalization

$516.25 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.12